Global Prescription Drugs Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 1,035.50 Billion |
 Market Size (Forecast Year) |
USD 1,892.90 Billion |
 CAGR |
% |
| Major Markets Players |
|
>全球处方药市场，按类型（品牌药、仿制药）、治疗领域（肿瘤学、免疫学、眼科学、呼吸学、皮肤病学、胃肠病学、泌尿学、妇科学、内分泌学、其他）、给药途径（口服、外用、肠胃外、其他）、最终用户（医院、专科诊所、家庭护理、其他）、分销渠道（医院药房、零售药房、网上药房、其他）划分 – 行业趋势和预测到 2031 年。
处方药市场分析和规模
在处方药市场领域，治疗疾病是主要应用。这些药物有助于管理和缓解与各种健康状况相关的症状，从头痛和过敏等常见疾病到糖尿病、高血压和癌症等慢性疾病。通过有针对性的药物干预，处方药可帮助患者恢复健康、控制慢性病并改善整体健康状况。它们通常是综合治疗计划的重要组成部分，与手术、物理治疗和生活方式改变等其他治疗方式协同作用。
2023 年全球处方药市场规模价值 11287 亿美元，预计到 2031 年将达到 22490 亿美元，2024 年至 2031 年预测期内的复合年增长率为 9.00%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。
报告范围和市场细分
|
报告指标 |
细节 |
|
预测期 |
2024-2031 |
|
基准年 |
2023 |
|
历史岁月 |
2022 (可定制为 2016-2021) |
|
定量单位 |
收入（单位：十亿美元）、销量（单位：台）、定价（美元） |
|
涵盖的领域 |
类型（品牌药、仿制药）、治疗领域（肿瘤学、免疫学、眼科学、呼吸学、皮肤病学、胃肠病学、泌尿学、妇科学、内分泌学、其他）、给药途径（口服、外用、肠胃外、其他）、最终用户（医院、专科诊所、家庭护理、其他）、分销渠道（医院药房、零售药房、网上药房、其他） |
|
覆盖国家 |
美国、加拿大、墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲其他地区、巴西、阿根廷和南美洲其他地区 |
|
涵盖的市场参与者 |
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Hikma Pharmaceuticals PLC (U.K.), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), Boehringer Ingelheim International GmbH. (Germany), Dr. 'Reddy's Laboratories Ltd. (India), Gilead Sciences, Inc. (U.S.), Amgen Inc. (U.S.), Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Lupin (India) |
|
Market Opportunities |
|
Market Definition
Prescription drugs are medications that can be obtained with a written prescription from a licensed healthcare provider such as a doctor or a nurse practitioner. These drugs are typically regulated due to their potential risks and require professional medical guidance for safe and effective use.
Prescription Drugs Market Dynamics
Drivers
- Rising Prevalence of Chronic Diseases Increases the Demand for Prescription Medications
With conditions such as cardiovascular diseases, diabetes, respiratory disorders, and cancer becoming increasingly common, there is a growing need for pharmaceutical interventions to manage symptoms and improve patient outcomes. As these conditions often require long-term medication regimens, the demand for prescription drugs remains consistently high. Pharmaceutical companies focus their research and development efforts on creating innovative drugs to address the specific needs of patients with chronic diseases, driving market growth.
- Growing Aging Population Fuels the Demand for Prescription Medications for Management
As individuals age, they are more prone to developing age-related health conditions, necessitating the use of prescription medications for management and treatment. With a larger proportion of the population entering older age brackets globally, there is a corresponding increase in the demand for prescription drugs to address the healthcare needs of this demographic. Pharmaceutical companies respond to this demand by developing specialized medications tailored to the needs of older adults, driving market growth.
Opportunities
- Expansion of Prescription Medications due to the Advancements in Pharmaceutical Research
Advancements in pharmaceutical research lead to the creation of novel therapies with enhanced efficacy, safety, and tolerability profiles, addressing unmet medical needs and expanding treatment options for various diseases. Cutting-edge technologies such as genomics, proteomics, and high-throughput screening enable more precise drug targeting and personalized medicine approaches, increasing therapeutic effectiveness and patient outcomes. The relentless pursuit of scientific innovation in pharmaceutical research fuels the expansion and evolution of the prescription drugs market.
For instance, The FDA approval of Zolgensma signifies a major stride in pharmaceutical research, offering hope to spinal muscular atrophy (SMA) patients. This gene therapy replaces the faulty gene, potentially stopping disease progression and enhancing quality of life, showcasing the transformative power of gene therapy in medicine.
- Increasing Expenditure on Healthcare Enhances Access to Healthcare Services
As healthcare budgets expand, there is a greater capacity for individuals and healthcare systems to afford prescription medications. This increased spending allows for greater investment in research and development by pharmaceutical companies, leading to the development of innovative drugs. Moreover, it enhances access to healthcare services, including prescription drugs, for a larger segment of the population. This trend fosters growth in the market as more patients can afford and access necessary medications, thereby driving demand and market expansion.
Restraints/Challenges
- Complex Regulatory Requirements for Smaller Pharmaceutical Companies
Stringent regulatory requirements encompass rigorous testing, documentation, and approval processes mandated by regulatory agencies, such as the FDA in the United States and the EMA in Europe. Compliance with these regulations adds substantial time and costs to drug development, hindering the speed at which new medications can reach the market. Moreover, the complexity of regulatory frameworks may deter smaller pharmaceutical companies from pursuing innovative drug development due to the resources required for compliance. This constraint limits market entry, stifles innovation, and can result in delays in bringing new, potentially life-saving drugs to patients in need..
- Growing Generic Competitors Limits the Growth of Prescribed Medications
The entry of generic competitors into the prescribed drugs market impacts the market dynamics. Generic alternatives often offer similar efficacy at lower costs, intensifying competition and eroding the market share of branded drugs. This increased competition can lead to price wars, squeezing profit margins for pharmaceutical companies. As a result, pharmaceutical companies face pressure to innovate and differentiate their products to maintain their competitive edge amidst the influx of generic alternatives.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In April 2020, Lupin Limited launched Mycophenolic Acid Delayed-Release Tablets USP in 180 mg and 360 mg variants. These tablets are designated for adult kidney transplant recipients and pediatric patients (aged 5 and above) who have undergone dialysis for at least six months, aiding in the prevention of organ rejection
- In March 2020, Dr. Reddy’s Laboratories Ltd. launched the generic version of Geodon (Ziprasidone Mesylate) injection in the U.S., catering to schizophrenia patients. This move offers a more cost-effective alternative for patients seeking treatment for their condition
Prescription Drugs Market Scope
The market is segmented on the basis of type, therapy area, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Branded
- Generic
Therapy Area
- Oncology
- Immunology
- Ophthalmology
- Respiratory
- Dermatology
- Gastroenterology
- Urology
- Gynaecology
- Endocrinology
- Others
Route of Administration
- Oral
- Topical
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Prescription Drugs Market Regional Analysis/Insights
The market is analyzed and market size insights and trends are provided by country, type, therapy area, route of administration, end-users and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.
北美在市场中占据主导地位，因为该地区拥有强大的医疗保健计划，推动了处方药的可及性和需求。主要制药公司已经建立了重要的业务，为市场的增长和创新做出了贡献。此外，该地区的疾病患病率激增，需要更多的药物干预。
受多种因素推动，亚太地区预计将出现显著扩张。政府旨在提高人们对医疗保健的认识的举措，加上研究活动的激增，都促进了这一增长。该地区拥有大量尚未开发的市场、庞大的人口基数以及对高质量医疗保健服务不断增长的需求，所有这些都推动了亚太地区医疗保健行业的发展。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
医疗保健基础设施增长安装基础和新技术渗透
该市场还为您提供每个国家/地区资本设备医疗支出增长、市场上不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对市场的影响的详细市场分析。数据适用于 2016-2021 年的历史时期。
竞争格局和处方药市场分析
市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对市场的关注有关。
市场上的一些主要参与者包括：
- F. Hoffmann-La Roche Ltd.（瑞士）
- Mylan NV（美国）
- Teva Pharmaceutical Industries Ltd.（爱尔兰）
- 赛诺菲（法国）
- 辉瑞公司（美国）
- 葛兰素史克公司 (英国)
- 诺华公司（瑞士）
- 默克公司（美国）
- 阿斯利康（英国）
- 强生私人有限公司（美国）
- Hikma Pharmaceuticals PLC（英国）
- 百时美施贵宝公司 (美国)
- 拜耳公司（德国）
- 勃林格殷格翰国际有限公司（德国）
- Dr.'Reddy's Laboratories Ltd.（印度）
- 吉利德科学公司（美国）
- 安进公司 (美国)
- 礼来公司 (美国)
- AbbVie Inc.（美国）
- 鲁冰花（印度）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
